id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-335003-7ae0galy	Kussmaul, William G.	COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy	2020-05-15		.txt	text/plain	739	54	57	Mackey and colleagues reported a systematic review that found high-certainty evidence that angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with greater illness severity in patients with COVID-19. The authors present data from 3 studies that found, with moderate certainty of evidence, no relationship of ACEI or ARB use with testing positive for the virus or becoming ill from it. On the basis of further data from 14 observational studies encompassing more than 23 000 adults with COVID-19, they found high-certainty evidence that the drugs are not associated with greater illness severity. As a result of this progression from fear and theory through data and multiple analyses from different continents, we now have reasonable reassurance that drugs that alter the renin-angiotensin system (RAS) do not pose substantial threats as either COVID-19 risk factors or severity multipliers. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?	./cache/cord-335003-7ae0galy.txt	./txt/cord-335003-7ae0galy.txt